The Latest Cardiac and Vascular News
– One in four physicians surveyed feel the “lack of technology or equipment to make an accurate diagnosis of coronary artery disease and peripheral artery disease” is a key obstacle to an accurate diagnosis – Over a third of surveyed patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease […]
– Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent – GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent – Global COVID-19 testing-related sales were $1.9 billion in the third quarter – Excluding COVID-19 testing-related sales, third-quarter sales […]
STOCKHOLM, Oct. 18, 2021 /PRNewswire/ — Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, has through its fully owned subsidiary Mentice Inc entered into an agreement with ABBOTT Inc. to provide simulation solutions for training of interventional devices. The order covers systems that will be offered […]
Accommodates a greater variety of patients and provides a more complete look at every patient’s heart with enhanced scanning capabilities, including a 76 percent increase in field-of-view volume[i] Leverages GE Healthcare’s exclusive Alcyone technology, which can view cardiac anatomy and pathology with great clarity and speed Introduces several new automated […]
– New enhancements to Abbott’s Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures – Epic Plus designed to help patients with more complex cases of aortic or mitral regurgitation or […]
– Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery – With Portico approval, Abbott offers the industry’s most comprehensive portfolio of structural heart solutions in the U.S. ABBOTT PARK, Ill., Sept. 20, 2021 /PRNewswire/ — Abbott (NYSE: ABT) […]
Acquisition builds upon Abbott’s leading vascular portfolio, adding mechanical thrombectomy devices for treating patients with peripheral blood clots ABBOTT PARK, Ill., Sept. 2, 2021 /PRNewswire/ — Abbott (NYSE: ABT) announced today that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood […]
– New data presented at ESC Congress 2021 and simultaneously published in Circulation show Amulet Occluder was superior in left atrial appendage (LAA) closure and noninferior on safety and effectiveness endpoints compared to Watchman device – Amulet device is the first and only minimally invasive option approved for LAA occlusion […]
– The GUIDE-HF study examined the potential impact of Abbott’s CardioMEMS™ HF System, a small implantable pulmonary pressure sensor, in an expanded patient population not currently approved for the device – Data from the GUIDE-HF trial suggests CardioMEMS can improve care for more types of patients battling heart failure and […]
– Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn’t needed following implantation – The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with […]
